CLINICAL TRIALS PROFILE FOR FENOGLIDE

All Clinical Trials for FENOGLIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02158273 ↗	Medication Development in Alcoholism: Investigating PPAR Agonists	Completed	National Institute on Alcohol Abuse and Alcoholism (NIAAA)	Phase 2	2014-05-01	The primary hypotheses under test are that alcohol dependent subjects treated with fenofibrate will report decreased craving for alcohol following cue-exposure in the laboratory and report less drinking post treatment relative to placebo.
NCT02158273 ↗	Medication Development in Alcoholism: Investigating PPAR Agonists	Completed	The Scripps Research Institute	Phase 2	2014-05-01	The primary hypotheses under test are that alcohol dependent subjects treated with fenofibrate will report decreased craving for alcohol following cue-exposure in the laboratory and report less drinking post treatment relative to placebo.
NCT06191133 ↗	Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma	Not yet recruiting	Lindsay Ferguson, MD	Phase 1	2024-08-01	Normally, p53 helps prevent tumors from forming in the body. Early studies have shown that Fenofibrate, a cholesterol-lowering drug, can restore normal function to p53 and can change the metabolism of HPV-positive tumors in a way that stops the growth of tumors. The purpose of this study is to understand how Fenofibrate can be used to treat HPV-positive cervical cancers and cervical dysplasia. Researchers will examine collected tissue samples and investigate various genes and proteins to see whether Fenofibrate has an effect on HPV-positive cervical cancers and cervical dysplasia.

Clinical Trial Conditions for FENOGLIDE

Condition Name

Condition Name for FENOGLIDE
Intervention	Trials
Alcoholism	1
Cervical Intraepithelial Neoplasia	1
Invasive Cervical Cancer	1

Condition MeSH

Condition MeSH for FENOGLIDE
Intervention	Trials
Uterine Cervical Dysplasia	1
Neoplasms	1
Carcinoma in Situ	1
Alcoholism	1

Clinical Trial Locations for FENOGLIDE

Trials by Country

Trials by Country for FENOGLIDE
Location	Trials
United States	1

Trials by US State

Trials by US State for FENOGLIDE
Location	Trials
California	1

Clinical Trial Progress for FENOGLIDE

Clinical Trial Phase

Clinical Trial Phase for FENOGLIDE
Clinical Trial Phase	Trials
Phase 2	1
Phase 1	1

Clinical Trial Status

Clinical Trial Status for FENOGLIDE
Clinical Trial Phase	Trials
Completed	1
Not yet recruiting	1

Clinical Trial Sponsors for FENOGLIDE

Sponsor Name

Sponsor Name for FENOGLIDE
Sponsor	Trials
National Institute on Alcohol Abuse and Alcoholism (NIAAA)	1
The Scripps Research Institute	1
Lindsay Ferguson, MD	1

Sponsor Type

Sponsor Type for FENOGLIDE
Sponsor	Trials
Other	2
NIH	1

FENOGLIDE: Clinical Trial Update, Market Analysis, and 2026-2036 Projection

Last updated: May 3, 2026

What is FENOGLIDE and what is the current clinical posture?

No sufficient, citable information is available in the provided context to identify the exact drug (active ingredient), its indication, or its clinical trial program. Without those inputs, a complete and accurate clinical update cannot be produced.

Which clinical trials exist for FENOGLIDE, and what are their statuses?

No sufficient, citable information is available in the provided context to enumerate FENOGLIDE trials (NCT identifiers, phases, endpoints, enrollment, interim results, or readouts).

What is the competitive market landscape for FENOGLIDE?

No sufficient, citable information is available in the provided context to determine:

• the therapeutic area and target,
• the geography (US/EU/China/ROW),
• the relevant standard of care,
• current competitor products (including branded and generic),
• pricing and reimbursement dynamics.

What market forecasts can be made for FENOGLIDE through 2036?

No sufficient, citable information is available in the provided context to build a defensible forecast model using inputs such as:

• addressable patient population,
• penetration assumptions,
• uptake curve,
• pricing and net revenue,
• label restrictions and payer behavior,
• patent exclusivity and competitive erosion.

What deal or patent signals affect valuation for FENOGLIDE?

No sufficient, citable information is available in the provided context to assess patent coverage, exclusivity, or litigation that would constrain market projections.

Key Takeaways

• No clinical trial, market, pricing, payer, or patent data tied to “FENOGLIDE” is available in the provided context, so a complete and accurate clinical update, market analysis, or 2026-2036 projection cannot be generated.

FAQs

1. What is FENOGLIDE’s active ingredient and indication?
   Cannot be determined from the provided context.

2. What phase is FENOGLIDE in and when are major readouts expected?
   Cannot be determined from the provided context.

3. What companies compete with FENOGLIDE and how do their products perform commercially?
   Cannot be determined from the provided context.

4. What pricing and reimbursement level should be used for revenue projections?
   Cannot be determined from the provided context.

5. Does FENOGLIDE face patent or regulatory exclusivity barriers?
   Cannot be determined from the provided context.

References

[1] No sources were provided in the prompt.